Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Crossbow Therapeutics, Inc.
Crossbow Therapeutics Doses First Patient in Phase 1 Trial of CBX-250 for Myeloid Malignancies
Today 8:30 EDT
From
Crossbow Therapeutics, Inc.
Via
Business Wire
Crossbow Therapeutics Nominates its Second Development Candidate, CBX-663, a Broadly Acting Therapeutic for a Wide Range of Solid and Hematologic Malignancies
July 23, 2025
From
Crossbow Therapeutics, Inc.
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.